Navigation Links
Pharma IQ's Solubility Report
Date:4/27/2012

LONDON, April 27, 2012 /PRNewswire/ --

Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.

The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.

In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.

The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.

The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.

Other important topics expressed by survey respondents and that will be discussed at the event include:

  • The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
  • The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • The use the knowledge and exp
    '/>"/>

SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Mass. , March 27, 2015 ... platform for drug discovery and development services which ... for the pharmaceutical industry, announced financial results for ... Timothy C.  Tyson, Chairman of XRpro Sciences ... to successfully transition from development stage to commercial ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International ... of myeloma patients while working toward prevention and a ... (D-NY) for introducing a federal resolution (H. Res. 174) ... 2015 as "National Multiple Myeloma Awareness Month." ... myeloma worldwide, and more than 110,000 new cases are ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... 21 /PRNewswire/ Terumo Heart, Inc. today,announced the discharge of ... Assist System (LVAS). The patient was,discharged home on August ... after receiving the device., The patient is a ... heart failure for nearly 20 years. He is the ...
... have a study,that is falling behind with recruitment? Have ... media but still have not seen the,desired results? Perhaps ... to help,your sites navigate the world of media placements ... Argonauta Assist(TM) service," says Ms. Ann Kottcamp,President of Argonauta ...
Cached Medicine Technology:Discharge of First U.S. DuraHeart(TM) Patient 2Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts 2
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... highlighted a problem which could prove critical to organizations ... system testing, a critical aspect of data security, is ... card industry data security report, every major category out ... scanning and penetration testing. “With all the craziness that ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... hip injuries is a growing field in orthopaedic medicine. ... with labral tear to confirm the pain etiology, research ... Medicine’s ( AOSSM ) Specialty Day suggests that pain ... outcomes following arthroscopic hip surgery. , “Our study ...
(Date:3/28/2015)... Francisco, California (PRWEB) March 28, 2015 Andrew ... for original 1960's Who psychedelic concert posters. The Who and ... New York on August 2, 1968. According to Hawley, “The ... playing many concert halls and college campuses. Perhaps the most ... performance with Jim Morrison and the Doors on August 2, ...
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Servpro ... , this week released a report about the link ... of asthma sufferers, and according to recent medical research, ... , According to the Environmental Protection Agency, people with ... reactions. Breathing in mold may trigger asthma attacks for ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... 11 Home Care Assistance of Eastern,Pennsylvania has ... Health, a leading, nationally-recognized provider of services to,Medicare ... appointments with specialized medical facilities, providing,transportation to and ... for approximately 1,400 members of Bravo Health. , ...
... ... Boulder Creek, CA (PRWEB) December 11, 2008 -- Two Illinois hospitals ... of their employees and have been rewarded for that commitment. Their ... each the ,HeartMath Hospital, designation and the ,Continuity of Care, award., ...
... 11 Bioenergy Life Science -- The Ribose,Company ... Solutions, LLC, to market,Bioenergy D-Ribose(TM) in the Eastern ... to stimulate the synthesis of adenosine,triphosphate (ATP) -- ... "Collaborating with Xsto Solutions will ...
... ) commented today on the performance outlook of the company for ... the company expects 2009 earnings per share to be in the ... Mr. Culp stated, "We have taken significant steps to prepare ... ahead. However, despite the current economic backdrop, we believe we are ...
... One protein was protective, the other not, researchers found , , ... insulin-related proteins are able to predict which patients with colon ... research suggests. , Insulin ushers blood sugar out of the ... efficiently in people who are obese, eat heavily and don,t ...
... , NEW YORK, Dec. 11 ... a promising trend of declining usage rates of certain drugs -- ... teens. However, it also indicates several areas of growing concern. ... , The long-term decline in methamphetamine use, especially ...
Cached Medicine News:Health News:Patient Care Means Employee Care at Illinois Hospitals 2Health News:Patient Care Means Employee Care at Illinois Hospitals 3Health News:Patient Care Means Employee Care at Illinois Hospitals 4Health News:Patient Care Means Employee Care at Illinois Hospitals 5Health News:Patient Care Means Employee Care at Illinois Hospitals 6Health News:Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose 2Health News:Danaher CEO Comments on Outlook 2Health News:2 Markers Predict Survival Odds in Colon Cancer Patients 2Health News:2 Markers Predict Survival Odds in Colon Cancer Patients 3Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: